The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
The partnership initially will focus on cardiovascular and kidney diseases
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Artificial intelligence coupled with laboratory automation will transform how scientific work is performed
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Subscribe To Our Newsletter & Stay Updated
